Introduction
A wealth of studies has demonstrated that depressed cardiac baroreflex sensitivity (BRS) is a powerful predictor of poor outcome, independent of other well-established markers in patients with heart failure with reduced ejection fraction (HFrEF).
1 -3 However, most of these studies were conducted before the routine use of combined neuroendocrine blockade and implantable devices, which may correct cardiovascular autonomic imbalance and favourably affect the outcomes in HFrEF. 4 -7 Furthermore, New York Heart Association (NYHA) functional class III-IV patients represented a significant proportion of the patients included in most previous studies; however, some data suggest that BRS impairment is not infrequent in mild-to-moderate HFrEF 8 and BRS evaluation may carry a prognostic value in these patients. 9 Therefore we aimed to assess the prognostic value and clinical correlates of BRS in contemporary patients with mild-to-moderate HFrEF receiving optimal management.
Methods

Study population
The study population consists of patients who were prospectively included into the SICA-HF (Studies Investigating Co-morbidities Aggravating Heart Failure) multicentre, observational study. 10 In brief, SICA-HF inclusion criteria were: clinically stable chronic heart failure (HF) of > 3 month duration with objective evidence of cardiac dysfunction as evidenced by at least one of the following: left ventricular ejection fraction (LVEF) ≤40%, or left atrial dimension > 4.0 cm, or N-terminal pro-B-type natriuretic peptide (NT-proBNP) >400 pg/mL [or B-type natriuretic peptide (BNP) >150 pg/mL]. Patients with previous heart transplantation, cardiac or embolic events within 6 weeks prior to the visit, and patients with known pregnancy, or on haemodialysis were excluded.
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The present analysis is retrospective and includes data from SICA-HF patients recruited in Wroclaw (Department of Heart Diseases, Wroclaw Medical University) between 2010 and 2014, all of whom had LVEF ≤ 40%, did not have atrial fibrillation or a permanent pacemaker, and who underwent autonomic testing (for protocol see below). The study protocol was approved by the local Ethics Committee. All subjects gave an informed consent. The study was conducted in accordance with the Declaration of Helsinki.
Study protocol
All participants underwent physical examination with standard laboratory tests, measurement of NT-proBNP (pg/mL) in the blood, standard transthoracic echocardiography, cardiopulmonary treadmill exercise testing [with the assessment of peak oxygen consumption (VO 2 ), ventilatory response to exercise -minute ventilation to carbon dioxide output (VE/VCO 2 ) slope 11 -and respiratory exchange ratio] and autonomic testing. All patients completed the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the KCCQ overall summary score was used. 12 All these investigations were performed after an inclusion into the study when a responsible physician considered a patient optimally pharmacologically treated according to the European Society of Cardiology guidelines. 13 
Autonomic testing
Autonomic testing was performed in the morning (9:00-11:00 a.m.), in the quiet, light attenuated room with the subject lying supine. Heart rate (HR, b.p.m.), systolic blood pressure (SBP, mmHg) and an electrocardiogram (ECG) were recorded continuously and non-invasively using NEXFIN HD device (BMEYE B.V., Amsterdam, The Netherlands) at a sampling rate of 1 kHz. HR was calculated based on the ECG.
After the equipment was attached, the subject rested for 5 min. This allowed the subject to familiarize with the study equipment, and the recording from this period was ignored. The next 30 min of recording was defined as the resting recording from which a 10 min fragment of an acceptable quality was isolated and used to calculate: (i) resting values of HR and SBP defined as the arithmetic averages from the entire 10 min recording; (ii) BRS using the sequence method; (iii) HR variability (HRV) indices. Next, the subject was instructed to synchronize the breathing rhythm with the rhythm of the metronome (6 breaths per minute, 0.1 Hz) presented on a laptop screen, and a 5 min controlled breathing assessment was performed. At the end, phenylephrine assessment was conducted. The resting recording, the controlled breathing assessment and the phenylephrine assessment were interspersed with ≥ 5 min breaks.
Baroreflex sensitivity assessment using the phenylephrine method
The assessment of BRS by the phenylephrine method was performed according to standard procedure originally described by Smyth et al. 15 using phenylephrine as a vasoconstrictor. 1, 16 Phenylephrine was given as an intravenous bolus, at a starting dose of 2 g/kg, to rise SBP by ≥ 15 mmHg. If SBP increase was not sufficient, phenylephrine dose was increased by 50 g per bolus until an adequate dose of phenylephrine was established. With this dose, an injection was repeated to achieve a total number of three successful injections. All injections were interspersed with ≥ 5 min breaks. For each successful injection, a regression line relating RR interval (RRI) to SBP was drawn and the slope of the regression line was calculated. The mean of the three slopes was considered as a measure of BRS (BRS-Phe, ms/mmHg). Each SBP value was paired with the RRI value of the corresponding cardiac cycle (SBP-ECG delay of 0 beat). All phenylephrine tests were conducted by the same researcher (M. O.) , and all data processing and BRS-Phe calculations were conducted by the same researcher (B.P.).
Baroreflex sensitivity assessment using the sequence method
From a continuous SBP and ECG recording, all sequences of ≥ 3 consecutive heart beats characterized by either simultaneous increase in SBP (by > 1.0 mmHg) and RRI (by > 4.0 ms) or simultaneous decrease in SBP (by > 1.0 mmHg) and RRI (by > 4.0 ms) were isolated. Only sequences with linear correlation coefficient for SBP and RRI > 0.80 were included. For each sequence included, a slope of the regression line relating SBP to RRI was calculated. The mean of all slopes was considered as a measure of BRS (BRS-Seq, ms/mmHg). 16 Any given SBP value was paired with accompanying RRI value (SBP-ECG delay of 0 beat), as this approach was reported to be the most appropriate. 17 Baroreflex sensitivity assessment using the controlled breathing method A 200 s recording of an acceptable quality was selected from a 5 min controlled breathing assessment recording and used to calculate BRS according to the method described by Davies et al. 18 From a continuous recording of SBP and ECG, the signal component at the frequency of 0.10 Hz was extracted. The ratio of the average amplitude of RRI oscillations to the average amplitude of SBP oscillations was considered as a measure of BRS (BRS-CtrBr, ms/mmHg).
All three methods for BRS evaluation have shown acceptable reproducibility in our laboratory (see online supplementary Table S1 ).
Heart rate variability analysis
Ectopic beats were corrected by interpolation. The following time-domain parameters of HRV were calculated: mean of RRIs (mean RR, ms), standard deviation of all RRIs (SDNN, ms), and the percentage of RRIs differing by > 50 ms (pNN50, %). To compare survival rates between HFrEF patients with low vs. preserved BRS and low vs. preserved HRV, patients were dichotomized according to the following cut-offs: (i) 3.0 ms/mmHg for BRS-Phe as proven prognosticator in patients with cardiac disease, 3 (ii) lowest tertiles for BRS-Seq, BRS-CtrBr, SDNN and pNN50. BRS-based comparisons were repeated using the cut-offs derived from receiver operating characteristic (ROC) curve analyses, to rule out the possible effect of sub-optimal cut-off selection. Log-rank test was used for low vs. high BRS group comparisons.
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Data and statistical analyses
Univariate and multivariate Cox proportional hazards models were used to assess relations between BRS and survival. Skewed distributed variables were log-transformed [natural logarithm, (ln)] to normalize the distribution before being included in the model. Multivariate analysis was performed using the backward elimination method (P < 0.15). A P-value of <0.05 was considered statistically significant.
The composite endpoint was all-cause death and appropriate and documented implantable cardioverter-defibrillator (ICD) discharge. All-cause mortality was ascertained from national identification database of the Polish Ministry of Digital Affairs. Data on ICD interventions were retrieved from medical records in all patients who had an ICD implanted. Only the first event in each patient was used in the subsequent analyses. The length of follow-up was censored at 5 years in all survivors.
Results
Baseline characteristics are presented in capacity, as evidenced by the vast majority being in NYHA class I-II with mean peak VO 2 of 20.2 ± 5.2 mL/kg/min. All patients were treated with a combination of an angiotensin-converting enzyme inhibitor and a beta-blocker. Among patients receiving an angiotensin-converting enzyme inhibitor, 47% achieved a recommended target dose and 81% received ≥ 50% of a recommended target dose. Among those treated with a beta-blocker, 19% and 65% received either a recommended target dose or ≥50% Spearman's correlation coefficient and P-value are presented. BRS-CtrBr, baroreflex sensitivity assessed by the controlled breathing method; BRS-Phe, baroreflex sensitivity assessed by the phenylephrine method; BRS-Seq, baroreflex sensitivity assessed by the sequence method; HFrEF, heart failure with reduced ejection fraction; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; pNN50, percentage of RR intervals differing by > 50 ms; RER, respiratory exchange ratio; SBP, systolic blood pressure; SDNN, standard deviation of all RR intervals; VE/VCO 2 , minute ventilation to carbon dioxide output; VO 2 , oxygen consumption.
of a recommended target dose, respectively. Among patients receiving an aldosterone antagonist, all received ≥ 50% of the target dose. Therapy with an angiotensin-converting enzyme inhibitor, a beta-blocker, or an aldosterone antagonist was initiated > 3 months before study evaluation in 90%, 91% and 77% of patients, respectively. The mean correlation coefficient of SBP-RRI slopes used for the calculation of BRS-Phe and BRS-Seq was 0.78 ± 0.15 and 0.97 ± 0.01, respectively.
Clinical and laboratory correlates of cardiac baroreflex sensitivity
Although there were significant correlations between BRS calculated with different methods and clinical and laboratory data, they all were modest-moderate ( Table 2) .
Thirty-four (35%) patients had depressed BRS-Phe (i.e. < 3.0 ms/mmHg) and these patients were older (60 ± 7 vs. 56 ± 10 years, P < 0.05), had higher uric acid [7. There was a trend toward lower LVEF (31 ± 6 vs. 33± 6%, P = 0.06) and KCCQ overall summary score (65 ± 21 vs. 73 ± 17 patients, P = 0.07) in this group. There were no other differences between low and preserved BRS-Phe groups (all P ≥ 0. 
Prognostic value of cardiac baroreflex sensitivity
During the follow-up (mean ± SD: 53 ± 15 months; censored at 60 months in all survivors), 23 patients died and 15 patients experienced at least one appropriate, documented ICD discharge. The composite endpoint was reached in 31 patients (the first event was all-cause death in 16 patients and appropriate ICD discharge in 15 patients).
The results of univariate Cox proportional hazards analysis are presented in Table 3 . BRS measures were not related to event-free survival (all P ≥ 0.28). When LVEF, SBP, uric acid (ln) and NT-proBNP (ln) (which appeared prognosticators in univariate analysis) were included in the multivariate analysis, only LVEF remained statistically significant ( = -0.11, hazard ratio 0.89, 95% confidence interval 0.84-0.95, P = 0.0006). There were no differences in survival rate between low vs. preserved BRS groups dichotomized according to either pre-selected cut-offs (3.0 ms/mmHg for BRS-Phe and lowest tertiles for BRS-Seq and BRS-CtrBr: 5.0 ms/mmHg and 5.8 ms/mmHg, respectively; all P ≥ 0.28) (Figure 1) or the cut-offs derived from ROC curve analyses (2.6 ms/mmHg for BRS-Phe, 6 .6 ms/mmHg for BRS-Seq, 9.7 ms/mmHg for BRS-CtrBr, all P ≥ 0.15) (online supplementary  Table S2 ). No differences in BRS measures were found between survivors and non-survivors (all P > 0.3) (online supplementary  Table S3 ).
Prognostic value of heart rate variability
Heart rate variability parameters were not related to survival in univariate Cox proportional hazards analysis (all P ≥ 0.15) ( Table 3) . No differences in survival rate were found between patients with low vs. preserved HRV according to pre-selected cut-offs (lowest tertiles for SDNN and pNN50: 22 ms and 0.50%, respectively).
Discussion
Our results call into question the prognostic usefulness of cardiac BRS assessment in the population of contemporary, optimally managed patients with mild-to-moderate HFrEF. We measured cardiac BRS using three different methods (including the 'gold standard' phenylephrine test) and obtained data on 5-year all-cause mortality and appropriate ICD discharges, but we failed to find any association between BRS and survival in this group. This may suggest that BRS impairment, although not infrequent in contemporary, optimally managed patients with mild-to-moderate HFrEF (NYHA class I-II), does not translate into worse outcomes. We acknowledge that our findings may not be generalized to all HFrEF patients. However, we believe that this study underscores the need for re-evaluation of the prognostic utility of BRS (and possibly other cardiac autonomic measures) in different subpopulations of patients with HF (see also online supplementary Table S4 ).
The vast majority of data referring to depressed BRS as an independent prognosticator in HFrEF included patients who did not receive contemporary, guideline-recommended pharmacological and device therapy. et al. 3 included 103 HFrEF patients treated with beta-blockers, with more severe HFrEF than in our study (as evidenced by lower LVEF and peak VO 2 and more patients in NYHA class III). Nevertheless, BRS was similarly depressed with 35% of patients with BRS-Phe < 3.0 ms/mmHg in our study vs. 31% in the La Rovere et al. 3 Also, the proportion of patients who reached the endpoint was similar between both studies (during a 29-month follow-up, 17% of patients experienced a cardiac event defined as cardiac death, appropriate ICD discharge, or urgent transplantation in the study by La Rovere et al. 3 vs. 32% who either died or had appropriate ICD during 53-month follow-up in our study). However, contrary to La Rovere et al., 3 we did not observe any difference in survival between patients with low vs. preserved BRS. Differences in drug and device therapy between our patients and the patients by La Rovere et al. 3 might play an important role. Although not specified by the authors, we assume that most of the patients of La Rovere et al. 3 may have not received aldosterone antagonists and statins (vs. 85% and 81% of our patients receiving these drugs, respectively), both of which may favourably influence BRS. In healthy volunteers, acute aldosterone infusion impairs cardiac 21 and sympathetic 22 BRS, while administration of aldosterone antagonist acutely enhances cardiac BRS. 6 Regarding statins, their beneficial effects on sympathovagal balance and BRS have been well documented in animal models of HFrEF; however, human studies have yielded less consistent results. 23 Additionally, potential differences in drug dosing between the current study and earlier studies might be of importance. Fifty percent (or more) of the recommend target dose of angiotensin-converting enzyme inhibitor, beta-blocker and aldosterone antagonist was achieved in 81%, 65% and 100%, of patients, respectively. Unfortunately, such data were not reported in most papers in this field. 2, 3 Baroreflex impairment has been proposed to be an important contributor to the autonomic imbalance (sympathetic predominance and vagal withdrawal), a cardinal feature of HFrEF. 24 Since this pattern of autonomic imbalance is associated with increased susceptibility for ventricular arrhythmias, a higher risk of sudden cardiac death and/or ICD shock can be expected in patients with depressed BRS. 25 Baroreceptor denervation in rats made them more susceptible to drug-induced ventricular arrhythmias, 26 whereas electrostimulation of carotid baroreceptor suppressed ventricular arrhythmias during acute ischaemia in dogs. 27 In line, low BRS identified post-myocardial infarction patients at high risk for arrhythmic mortality in the ATRAMI study. 28 A recent analysis of data from > 40 000 HFrEF patients enrolled in 12 randomized clinical trials (conducted between 1995 and 2014) indicated 44% decline over time in the rates of sudden death 29 which can be attributed to cumulative benefit of guideline-recommended medications. Current pharmacotherapy of HFrEF, along with the widespread use of device therapy, reduced the occurrence of life-threatening arrhythmias and sudden cardiac death in the HFrEF setting, thereby possibly reducing a direct impact of low BRS on cardiac mortality. While data on the cause of death were not available in the current study, we decided to include appropriate ICD discharge in the composite endpoint. Nevertheless, we did not observe any difference in event-free survival between patients with low vs. preserved BRS.
Potential implications in the light of novel device-based therapies targeting autonomic imbalance in HFrEF 24 -baroreflex activation therapy 30 and vagus nerve stimulation 31 -merit comment. There is an ample evidence confirming intact arterial baroreceptor control of sympathetic activity in HF allowing to believe that electrical carotid baroreflex activation would be efficient and potentially beneficial. 24 However, it is still unknown whether BRS is a modifiable risk factor. The estimated completion date of data collection for primary outcome measures (rate of cardiovascular mortality and HF morbidity) in the BeAT-HF trial (Barostim Neo-Baroreflex . Furthermore, it should be clearly acknowledged that the study population included rather young HF patients, mostly in NYHA class I-II, and therefore is not representative of the overall HF population. In particular, the study population is importantly different from the subset of HF patients suggested to benefit from baroreflex activation therapy (i.e. patients in NYHA class III). 30 The main conclusion is that depressed BRS, although frequently observed in contemporary, optimally managed patients with mild-to-moderate HFrEF (mostly NYHA class I-II), does not translate into worse outcomes. However, it should be underlined that the present study does not rule out the value of BRS assessment for risk stratification of patients at their initial manifestation of HF, i.e. at the time when the management strategy has to be determined. Moreover, risk of events in HF patients is evolving over time and in parallel autonomic cardiac modulation might have changed accordingly. Therefore, a time-varying analysis of the predictive value of BRS and HRV would have been more appropriate. However, it was not possible in this study, due to the fact that assessment of BRS and HRV was performed only at baseline.
The finding that BRS is depressed in mild-to-moderate HFrEF patients despite disease-modifying therapies is concordant with our previous reports on overactive peripheral chemoreceptors, as an element of abnormal autonomic pattern in the contemporary HFrEF population. 32 Importantly, resection of carotid bodies (containing peripheral chemoreceptors) reduced sympathetic nerve activity at rest in HFrEF patients. 33 Baroreflex sensitivity assessed by the phenylephrine method was associated with clinically important variables, while the patterns of correlations found for non-invasive BRS measures were less consistent. These results are in accordance with other reports demonstrating that the phenylephrine method is clinically more informative than other, non-invasive measures of BRS. 34 -36 However, although statistically significant, these relationships were rather modest, which may indicate that variability in BRS is rather influenced by other factors not directly related to the 'classical' measures of HF severity.
Study limitations
Our study was retrospective in nature and included a relatively small number of patients. However, according to the design of the study, all patients consecutively recruited in the SICA-HF project who gave a consent participated in the autonomic assessment. Regarding the size of the study, it seems to be one of the biggest comprehensively evaluating autonomic control in contemporary, optimally managed HFrEF patients. Notwithstanding this, the relatively small sample size may raise the question on whether the study was adequately powered to detect a difference in mortality between low vs. preserved BRS patients. However, La Rovere et al.
using the mortality rates reported by La Rovere et al. 3 for the patients treated with beta-blockers (53% vs. 14% for low vs. high BRS-Phe groups, respectively) and current groups size, setting the type I error (significance) and type II error (1 -Power) probability at 0.05.
Our findings refer to a population with mild-to-moderate HFrEF, with relatively well preserved functional capacity. However, both HF with mid-range (HFmrEF) and preserved ejection fraction (HFpEF) are characterized by a similar pattern of autonomic imbalance and therefore novel device-based therapies targeting autonomic nervous system are now tested in HFmrEF/HF/HFpEF patients. 37 -39 Information on the level of physical activity was not collected. Exercise training improves autonomic function via numerous mechanisms, of which a decrease in the activity of overactive skeletal muscle ergoreceptors plays an important role in patients with HFrEF. 40, 41 Also, other autonomic indices (e.g. postural test 42 ) may carry prognostic value in HF and further studies are needed to verify its prognostic usefulness in the contemporary HF population.
We did not include patients with atrial fibrillation in the current study. Lack of survival benefit of beta-blocker therapy in patients with HFrEF and atrial fibrillation may suggest that the pattern of neurohormonal activation in HFrEF patients with and without atrial fibrillation differs. 43 Additionally, our methods for BRS and HRV assessment exclude patients with permanent atrial fibrillation.
Neither screening for sleep-disordered breathing nor sleep studies were part of the SICA-HF protocol in our institution. Particularly, the obstructive sleep apnoea syndrome has been shown to depress BRS. 44 Given the fact that baroreflex control of HR (assessed in our study) and of sympathetic nervous system can be differently affected, it would be of interest to assess sympathetic BRS. Although it is generally accepted that the baroreflex control of cardiac function is markedly impaired in HF, the baroreflex-mediated regulation of sympathetic drive in HF patients has been found to be impaired by some investigators 8, 45 and intact by others. 46, 47 The latter view gains considerable support, 24 and the upward shift of the set point for adrenergic outflow in HF has been proposed. 48 Finally, we did not collect information on the cause of death in our patients, and therefore we were not able to inspect the prevalence of sudden cardiac death. Neither the data on HF hospitalizations were available.
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